Effect of Locally Delivered Minocycline on the Profile of Subgingival Bacterial Genera in Patients with Periodontitis: A Prospective Pilot Study

Biomolecules. 2022 May 18;12(5):719. doi: 10.3390/biom12050719.

Abstract

This prospective pilot study aimed to evaluate the effect of minocycline-HCl ointment (MO), locally delivered as an adjunct to scaling and root planing (SRP), on subgingival microflora. A total of 59 periodontitis patients received SRP as an initial periodontal therapy. In the selected periodontal pockets with probing depths (PD) of 6−9 mm, the sites that exhibited a positive reaction following a bacterial test using an immunochromatographic device were subsequently treated with MO (SRP + MO group, n = 25). No additional treatment was performed at sites showing a negative reaction (SRP group, n = 34). In addition to subgingival plaque sampling, measurement of clinical parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), plaque index and gingival index (GI) were performed at baseline and 4 weeks after the initial periodontal therapy. The subgingival microflora were assessed by terminal restriction fragment-length polymorphism analysis. Relative to baseline values, the mean scores for PD-, CAL-, BOP-, and GI-sampled sites were significantly decreased post treatment in both groups (p < 0.01). The intra-comparisons showed a significant decrease in the counts of the genera Eubacterium, Parvimonas, Filifactor, Veillonella, Fusobacterium, Porphyromonas, Prevotella, and unknown species in the SRP + MO group (p < 0.05). Inter-comparisons indicated a significant decrease in the genera Veillonella in the SRP + MO group (p = 0.01). Combination therapy of SRP and local MO induced a change in the subgingival microbial community: particularly, the number of Veillonella spp. was markedly reduced.

Keywords: Veillonella; adjunct treatment; bacterial genus; local drug-delivery system; minocycline-HCl; periodontitis; scaling and root planing; subgingival microflora.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Minocycline* / pharmacology
  • Minocycline* / therapeutic use
  • Periodontitis* / drug therapy
  • Pilot Projects
  • Prospective Studies
  • Root Planing

Substances

  • Minocycline

Grants and funding

This study was funded by the authors’ institutions and supported in part by research funds from Denka Seiken (Tokyo, Japan) and GC Showayakuhin Corporation (Formerly, Showa Yakuhin Kako Co. Ltd.) (Tokyo, Japan).